Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Prime Medicine, Inc. (PRME)
NASDAQ:PRME
RESEARCH TOOLSreports
Prime Medicine, Inc. (PRME) Stock Price & Analysis
73 Followers
PRME Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$5.17 - $17.20
Previous Close$5.27
Volume60.04K
Average Volume (3M)686.23K
Market Cap
$640.09M
Enterprise Value$624.53M
Total Cash (Recent Filing)$41.57M
Total Debt (Recent Filing)$13.63M
Price to Earnings (P/E)-2.5
Beta2.19
Next Earnings
May 09, 2024EPS Estimate
-$0.46Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.14
Shares Outstanding119,939,247
10 Day Avg. Volume702,704
30 Day Avg. Volume686,231
Standard Deviation0.16
R-Squared0.09
Alpha-0.05
Financial Highlights & Ratios
Price to Book (P/B)4.90
Price to Sales (P/S)3762.38
Price to Cash Flow (P/CF)-3.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.72K
Enterprise Value/Gross Profit3.72K
Enterprise Value/Ebitda-4.07
Forecast
1Y Price Target
$16.75Price Target Upside223.98% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Prime Medicine, Inc. News
Bulls Say, Bears Say
Bulls Say
Regulatory ApprovalFDA approval of PM359 IND is expected, which may significantly increase investor confidence and support the stock's growth prospects.
Strategic PartnershipsThe company's advancement in its pipeline and generation of key preclinical data is attracting favorable partnerships, which could enhance its financial stability and boost its market position.
Technology DifferentiationPrime editing's high specificity and versatility could offer superior and broader applicability than other gene editing approaches, potentially leading to a competitive edge in the market.
Bears Say
Financial StabilityThe company currently only has cash runway through 2024 with limited catalysts over the next months.
Product DevelopmentThe most attractive programs are also the most technically challenging, suggesting that advancement into the clinic could be multiple years away.
Research And DevelopmentThe clinical development path for Prime's 18 pipeline programs remains unclear.
---
Ownership Overview
80.49% Insiders
6.11% Mutual Funds
11.39% Other Institutional Investors
2.01% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PRME FAQ
What was Prime Medicine, Inc.’s price range in the past 12 months?
Prime Medicine, Inc. lowest stock price was $5.17 and its highest was $17.20 in the past 12 months.
What is Prime Medicine, Inc.’s market cap?
Currently, no data Available
When is Prime Medicine, Inc.’s upcoming earnings report date?
Prime Medicine, Inc.’s upcoming earnings report date is May 09, 2024 which is in 20 days.
How were Prime Medicine, Inc.’s earnings last quarter?
Prime Medicine, Inc. released its earnings results on Mar 01, 2024. The company reported -$0.72 earnings per share for the quarter, missing the consensus estimate of -$0.556 by -$0.164.
Is Prime Medicine, Inc. overvalued?
According to Wall Street analysts Prime Medicine, Inc.’s price is currently Undervalued.
Does Prime Medicine, Inc. pay dividends?
Prime Medicine, Inc. does not currently pay dividends.
What is Prime Medicine, Inc.’s EPS estimate?
Prime Medicine, Inc.’s EPS estimate is -$0.46.
How many shares outstanding does Prime Medicine, Inc. have?
Prime Medicine, Inc. has 119,939,250 shares outstanding.
What happened to Prime Medicine, Inc.’s price movement after its last earnings report?
Prime Medicine, Inc. reported an EPS of -$0.72 in its last earnings report, missing expectations of -$0.556. Following the earnings report the stock price went up 1.275%.
Which hedge fund is a major shareholder of Prime Medicine, Inc.?
Among the largest hedge funds holding Prime Medicine, Inc.’s share is ARK Investment Management LLC. It holds Prime Medicine, Inc.’s shares valued at 28M.
---
Prime Medicine, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$16.75 (223.98% Upside)
$16.75 (223.98% Upside)
Blogger Sentiment
Bullish
PRME Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 264.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $60.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 1.4%
Last 30 Days ▲ 3.0%
Last 30 Days ▲ 3.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-60.64%
12-Months-Change
Fundamentals
Return on Equity
-88.19%
Trailing 12-Months
Asset Growth
-26.46%
Trailing 12-Months
Company Description
Prime Medicine, Inc.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs.
---
PRME Stock 12 Months Forecast
Average Price Target
$16.75
▲(223.98% Upside)
Technical Analysis
Best Analysts Covering PRME
1 Year
1 Year Success Rate
0/5 ratings generated profit
1 Year Average Return
-29.78%
assigned a buy rating 8 days ago
Copying Kostas Biliouris's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -29.78% per trade.
---